Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.49 |
| ▸ | KDM5A | P29375 | 5/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.49 |
| ▸ | KDM4A | O75164 | 2/20 | 0.49 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3882025 | 0.91 | KDM4C (0.48) | KDM4CKDM5AKDM5BKDM4ANR4A2 | |
| SCHEMBL3888336 | 0.84 | KDM4C (0.55) | KDM4CKDM5AKDM5BKDM4AALKBH1 | |
| SCHEMBL3873589 | 0.80 | HSP90AB1 (0.53) | KDM4CKDM5AKDM5BKDM4ANR4A2 | |
| SCHEMBL3874813 | 0.78 | HSP90AB1 (0.46) | KDM4CKDM5AKDM5BKDM4AMAOB | |
| SCHEMBL3874573 | 0.77 | HSP90AB1 (0.50) | KDM4CKDM5AKDM5BKDM4ANR4A2 | |
| SCHEMBL3875988 | 0.77 | CYSLTR1 (0.55) | KDM4CKDM5AKDM5BKDM4AHSP90AB1 | |
| SCHEMBL3877722 | 0.77 | EGLN1 (0.55) | KDM4CKDM5AKDM5BALKBH1MAOB | |
| SCHEMBL3880975 | 0.77 | EGLN1 (0.53) | KDM4CKDM5AKDM5BKDM4AALKBH1 | |
| SCHEMBL3874651 | 0.76 | EGLN1 (0.54) | KDM4CKDM5AKDM5BKDM4AMAOB | |
| SCHEMBL3877786 | 0.76 | KDM4C (0.45) | KDM4CKDM5AKDM5BKDM4AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673955-B2 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | MERCK PATENT GMBH (DE) | 2014-03-18 | — | — | US | claimed |
| EP-1910305-B1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2009-08-26 | — | — | EP | claimed |
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | claimed |
| EP-1910305-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019937-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | claimed |
| EP-1752450-A1 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | Merck Sante (FR) | 2007-02-14 | — | — | EP | claimed |
| US-8673955-B2 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | MERCK PATENT GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| EP-1910305-B1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-1910305-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019937-A1 | IMIDAZOLE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| EP-1752450-A1 | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them | Merck Sante (FR) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312299-A1 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them | FBP1, ALDOA, GYS2 | KDM4C 3197/4885KDM5A 2180/4885KDM5B 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.